Gencoglan G.Inanir I.Miskioglu M.Gunduz K.2024-07-222024-07-22201815569527http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/15038Purpose: Isotretinoin is the most effective drug for acne with some side effects. Few studies exist regarding the effects of isotretinoin on haematological parameters with different results. Mostly, baseline values with a single value during or at the end of the treatment were compared. In this study, we aimed to determine the differences in haematological parameters during isotretinoin treatment until reaching the cumulative dose of 120 mg/kg. Materials and methods: The study included 118 patients with moderate-to-severe acne vulgaris. Patients with preexisting liver disease, anaemia, iron deficiency, abnormal liver function tests, thrombocytopenia/thrombocytosis or hyperlipidaemia were excluded. Laboratory monitoring for haematological parameters was performed at baseline and monthly during treatment. Parameters at the baseline, at the first and second months and at the end of the therapy were taken into account. Results: According to general linear model analysis, platelets and plateletcrit increased at the first month of the treatment and then decreased to baseline. White blood cells and neutrophils decreased at the first month, then increased to baseline value at the second month, and were found to be decreased again at the end of the treatment. Mean corpuscle volume was found to be increased at the end of the treatment. Other parameters in CBC did not show statistically significant differences. Conclusions: Although some changes occur in haematological parameters during isotretinoin therapy, all of these changes remain within the normal range. Evaluating the spot values at any time during treatment may cause misinterpretations. © 2017 Informa UK Limited, trading as Taylor & Francis Group.EnglishAcne VulgarisAdolescentAdultBlood Cell CountDermatologic AgentsErythrocyte IndicesFemaleHumansIsotretinoinMaleMiddle AgedYoung Adultisotretinoindermatological agentisotretinoinacne vulgarisadolescentadultArticledisease severitydrug effectevaluation studyfemalehematocrithematological parametershumanleukocytemajor clinical studymalemean corpuscular hemoglobinmean corpuscular volumeneutrophilacne vulgarisbloodblood cell countclinical trialdrug effectmiddle agedyoung adultArticle10.1080/15569527.2017.1359837